组织碎化术消融骨肿瘤:离体犬骨肉瘤肿瘤的可行性研究
本研究在离体犬骨肉瘤样本上评估500 kHz组织碎化术消融原发骨肉瘤的可行性。所有肿瘤样本在峰值负压26.2±4.5 MPa下均产生气泡云,组织病理显示治疗区有效细胞消融,而正常骨和神经无细胞死亡或组织损伤。经皮肤/软组织治疗也能在肿瘤内形成局限的气泡云和消融区。
要点
- 组织碎化术可经完整皮肤/软组织在骨肉瘤内产生局限消融区。
- 峰值负压26.2±4.5 MPa下所有肿瘤样本均产生气泡云。
- 正常骨和神经在相同参数下未见细胞死亡或组织损伤。
诊断标准与关键数值
- 所有肿瘤样本在峰值负压26.2±4.5 MPa下于焦点处产生气泡云。
- 组织病理显示治疗区骨肉瘤肿瘤有效细胞消融,正常组织无细胞死亡或组织损伤。
- 经组织/皮肤治疗可在骨肉瘤肿瘤内产生局限的气泡云和消融区。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Osteosarcoma (OS) is a primary bone tumor affecting both dogs and humans. Histotripsy is a non-thermal, non-invasive focused ultrasound method using controlled acoustic cavitation to mechanically disintegrate tissue. In this study, we investigated the feasibility of treating primary OS tumors with histotripsy using a 500-kHz transducer on excised canine OS samples harvested after surgery at the Veterinary Teaching Hospital at Virginia Tech. Samples were embedded in gelatin tissue phantoms and treated with the 500-kHz histotripsy system using one- or two-cycle pulses at a pulse repetition frequency of 250 Hz and a dosage of 4000 pulses/point. Separate experiments also assessed histotripsy effects on normal canine bone and nerve using the same pulsing parameters. After treatment, histopathological evaluation of the samples was completed. To determine the feasibility of treating OS through intact skin/soft tissue, additional histotripsy experiments assessed OS with overlying tissues. Generation of bubble clouds was achieved at the focus in all tumor samples at peak negative pressures of 26.2 ± 4.5 MPa. Histopathology revealed effective cell ablation in treated areas for OS tumors, with no evidence of cell death or tissue damage in normal tissues. Treatment through tissue/skin resulted in generation of well-confined bubble clouds and ablation zones inside OS tumors. Results illustrate the feasibility of treating OS tumors with histotripsy.
引用
- Arnold L, Hendricks-Wenger A, Coutermarsh-Ott S, et al. Histotripsy Ablation of Bone Tumors: Feasibility Study in Excised Canine Osteosarcoma Tumors. Ultrasound Med Biol. 2021. PMID: 34462159. doi:10.1016/j.ultrasmedbio.2021.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。